GHR

(redirected from Growth hormone receptor)
Also found in: Acronyms, Wikipedia.

GHR

A gene on chromosome 5p13-p12 that encodes growth hormone receptor, a type-I cytokine receptor which, once GH is bound, dimerizes and activates the JAK2/STAT5 transduction pathway, leading to growth.

Molecular pathology
Defects in GHR cause Laron type dwarfism.
Mentioned in ?
References in periodicals archive ?
growth hormone (gh), growth hormone receptor (ghr), insulin-like growth factor 1 (igf-1), insulin-like growth factor receptor (igf-1r), insulin-like growth factor binding protein 1 (igfbp-1), ghrelin (ghrl), cholecystokinin (cck) and glucokinase (gck), thyroglobulin (tg).
Differential intracellular signalling properties of the growth hormone receptor induced by the activation of an anti-GHR antibody.
Gender-specific expression of multiple estrogen receptors, growth hormone receptors, insulin-like growth factors and vitellogenins, and effects of 17 beta-estradiol in the male tilapia (Oreochromis mossambicus).
Growth hormone receptor gene expression in porcine skeletal and cardiac muscles is selectively regulated by postnatal undernutrition.
GROWTH HORMONE RECEPTOR (GHR) AND ITS INTRACELLULAR SIGNALING
Developmental expression of hepatic growth hormone receptor and insulin-like growth factor-I mRNA in the chicken.
Therefore, the present study is aimed to elucidate the mechanisms underlying the action of CLA on fat deposition through examination of the hormones which are related with fat metabolism and mainly secreted by adipose tissue, and on the target gene of growth hormone (GH) including growth hormone receptor (cGHR), insulin-like growth factor-1 (cIGF-1) and its I receptor (cIGF-IR) in abdominal fat, and cPPAR[gamma], cAdiponectin and its I receptor (cAdipoIR) in abdominal fat of broiler chickens.
The growth hormone-binding protein in rat serum is an alternatively spliced form of the rat growth hormone receptor.
As Executive Vice President of Sensus, a biotech company founded in Austin and subsequently acquired by Pharmacia (Pfizer), Davis was instrumental in the successful registration of Somavert(R), a growth hormone receptor antagonist, in the US, Europe and Japan.
That market is currently dominated by once-a-month Sandostatin LAR(R) Depot (octreotide acetate for injectable suspension) from Novartis (NYSE: NVS) and includes daily injections of Somavert (pegvisomant for injection), a growth hormone receptor antagonist, from Pfizer (NYSE: PFE).
SOMAVERT is the first in a new class of medicines called growth hormone receptor antagonists.

Full browser ?